<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122915</url>
  </required_header>
  <id_info>
    <org_study_id>CONCEPT</org_study_id>
    <nct_id>NCT00122915</nct_id>
  </id_info>
  <brief_title>CONCEPT: Crossover Efficacy Pain Trial in Motor Cortex Stimulation for Intractable Neuropathic Pain</brief_title>
  <official_title>A Prospective, Randomized, Double Blind, Crossover, Multi-center Study to Evaluate the Safety and the Efficacy of Motor Cortex Stimulation With the Cortical Stimulation Lead Model 2976 in Patients With Neuropathic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedtronicNeuro</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedtronicNeuro</source>
  <brief_summary>
    <textblock>
      The CONCEPT study has been designed to evaluate the safety and the efficacy of Motor Cortex
      Stimulation (MCS) with a new cortical lead (circular lead, eight electrodes, Medtronic Inc,
      Minneapolis, USA) in the treatment of intractable neuropathic pain, in particular for central
      post-stroke pain (CPSP) and trigeminal neuropathic pain (TGN)/facial pain.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on a consistently low enrolment rate and procedural challenges that were unknown at study
    start. It was not based on safety or efficacy concerns.
  </why_stopped>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events reports</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain assessed by Visual Analogue Scale (VAS)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic, sedative or psychoactive medication intake</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Pain, Intractable</condition>
  <condition>Facial Pain</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cortical lead, 8 electrodes (Model 2976) with Synergy neurostimulator</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CPSP or TGN/facial pain refractory to other medical treatments

          -  Pain &gt; 1 year prior to baseline

          -  Pain intensity with an average daily VAS score &gt; 5 demonstrated by 12 ratings across 4
             days

          -  Stable pain medication for &gt; 1 month prior to baseline

        Exclusion Criteria:

          -  CPSP with important paresis/severe motor deficit in the area of pain

          -  TGN/facial pain with complete deafferentation pain

          -  Atypical facial pain, i.e. when objective evidence for neuropathic facial pain
             syndromes is lacking and when specific psychological and behavioral factors can be
             identified

          -  Pain associated with malignant neoplastic disease anywhere in the body or head

          -  History of epilepsy

          -  Presence of a deterioration of cognitive functions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bart Nuttin, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck, Universitätsklinik für Neurochirurgie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Erasme, Service de Neurochirurgie</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL St luc, Neurochirurgie</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St Lucas, Neurochirugie</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg , Department of Neurosurgery</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Middelares ZH</name>
      <address>
        <city>Saint Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Philipps-Universität Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Creu I Sant Pau, Servicio de Neurocirugia</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Maranon, Servicio de Neurologia</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2005</study_first_submitted>
  <study_first_submitted_qc>July 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Motor Cortex Stimulation</keyword>
  <keyword>Pain treatment</keyword>
  <keyword>Central post-stroke pain (CPSP)</keyword>
  <keyword>Trigeminal neuropathic pain (TGN)</keyword>
  <keyword>Facial pain</keyword>
  <keyword>Neurostimuation</keyword>
  <keyword>Cortical lead</keyword>
  <keyword>Neuropathic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Facial Pain</mesh_term>
    <mesh_term>Pain, Intractable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

